SAGE Therapeutics Inc

SAGE Therapeutics Inc is a biopharmaceutical company that specializes in developing novel medicines for central nervous system (CNS) disorders. Their focus is on discovering and developing therapies that target the underlying biology of CNS disorders, such as depression, anxiety, and rare epilepsies. Their lead product candidate, ZULRESSO™ (brexanolone) injection, was approved by the FDA in March 2019 for the treatment of postpartum depression (PPD). SAGE is also developing a pipeline of potential therapies for other CNS disorders, including major depressive disorder (MDD), essential tremor, and Parkinson's disease. SAGE is committed to improving the lives of patients with CNS disorders by advancing innovative treatments that address unmet medical needs.